Consistent with these observations and the known involvement of PACE4 in prostate adenocarcinoma progression, we aimed to evaluate the relationship between both ERG expression and PACE4-altCT expression in prostate primary tumor tissues and its potential as a biomarker using biochemical recurrence as an outcome. This evidence concerns the gene ERG and prostate adenocarcinoma.